Ref: Syn/CS/SE/PR/July/2019-20/31

Syngene

Syngene International Limited
Biocon Park SEZ, Bommasandra IV Phase,
Jigani Link Road, Bangalore 560 099,
India.
T +91 80 2808 2808
F +91 80 4014 3150 / 2852 3423
CIN No. L85110KA1993PLC014937
www.syngeneintl.com

July 1, 2019

To,	To,
The Manager Listing	The Manager Listing
BSE Limited	National Stock Exchange of India Limited
Corporate Relationship Department	Corporate Communication Department
Dalal Street, Mumbai – 400 001	Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	**Scrip Symbol: SYNGENE**

Dear Sir/Madam,

Subject: Appointment of Dr. Mahesh Bhalgat as Chief Operating Officer

We wish to inform you that we have appointed Dr. Mahesh Bhalgat, as Chief Operating Officer with effect from July 1, 2019.

Please find enclosed the press release announcing the same. The press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and record.

Thanking You,

Yours faithfully,
For **SYNGENE INTERNATIONAL LIMITED**

M.B Chinappa
CFO and Compliance Officer

Syngene International Limited ★ Bangalore ★

PB



Syngene Appoints Dr. Mahesh Bhalgat as COO

July 1, 2019, Bengaluru, India

Syngene International Limited, a leading global Contract Research Organisation, today announced the appointment of Dr. Mahesh Bhalgat as Chief Operating Officer (COO). Dr. Bhalgat will take charge as COO with effect from 1st July, 2019. He comes to Syngene from Shantha Biotechnics, a Sanofi company, where he was responsible for all manufacturing operations, supply chain, engineering projects, HSE, manufacturing excellence and administrative services.

Commenting on the new appointment, Jonathan Hunt, Chief Executive Officer, Syngene International said, *"We are delighted to have Dr. Bhalgat join the Syngene executive leadership team. Syngene has evolved to be a global scale scientific services provider and Dr. Bhalgat's significant expertise in R&D, analytical development, technology transfer, regulatory sciences and quality will further enhance Syngene's position as a global CRO."*

In a career spanning over 25 years in the field of biotechnology and biologics, Dr. Bhalgat is recognised for his contribution to the commercialization of diagnostic kits, biopharmaceuticals and WHO pre-qualification of vaccines. He has rich experience in diverse areas of biotechnology such as biotherapeutics, vaccines, ag-biotech, and research reagents and has been associated with companies such as Amgen, Monsanto, Celera Genomics, Thermo Fisher, Biological E.

A Ph.D. in Medicinal Chemistry from the University of Utah, he is the Co-Chair of CII's National Committee of Biotechnology as well as a member of the Biomeriux Scientific Advisory Board, France, United States Pharmacopeia, GCBA committee and the Indian Pharmacopeial Commission.

About Syngene



Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022), is an innovation focused global discovery, development and manufacturing organisation providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world. Syngene's clientele include world leaders such as Bristol-Myers Squibb, Baxter, Amgen, GSK, Merck KGaA and Herbalife. Its innovative culture is driven by the passion of its 4000 strong team of scientists who work with clients from around the world to solve their scientific problems, improve R&D productivity, speed time to market and lower the cost of innovation. For more details, visit www.syngeneintl.com.

Contact details

Investor Contact	**Media Contact**
Chanderlekha Nayar P: +91 80 6775 8821 M: +91 72591 92001 Fax: +91 80 2852 3423 E: chanderlekha.nayar@syngeneintl.com	Sandeep Nair P: +91 80 6775 8775 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com